21:22 , Jan 31, 2019 |  BC Innovations  |  Emerging Company Profile

Apic: Dual-gene therapies

Apic Bio Inc.'s APB-101 is a dual-function gene therapy for AAT deficiency that silences the mutant AAT gene and augments wild-type AAT expression, which the company believes gives it greater efficacy and lower liver toxicity...
17:41 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Venture roundup: Apic, Stelexis, Biond, Keros

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) and cancer company Stelexis Therapeutics LLC (New York, N.Y.) each announced series A rounds of at least $40 million. Other companies that announced venture rounds include Biond...
23:42 , Jan 8, 2019 |  BC Extra  |  Financial News

Venture roundup: Apic, Stelexis, Biond, Keros

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) and cancer company Stelexis Therapeutics LLC (New York, N.Y.) each announced series A rounds this week of at least $40 million. Other companies that announced venture rounds...
20:53 , Oct 12, 2018 |  BC Extra  |  Tools & Techniques

iPS cell-derived models offer new opportunities for drug screening

New models for Down syndrome and amyotrophic lateral sclerosis harness patient-derived induced pluripotent stem (iPS) cells to overcome genetic and cell heterogeneities inherent to the disorders not adequately recapitulated by cell culture and animal models....
17:26 , Jul 20, 2018 |  BC Week In Review  |  Financial News

DFJ leads Verge Genmics' $32M series A round

Neuroscience company Verge Genomics Inc. (San Francisco, Calif.) raised $32 million in a series A round led by DFJ on July 16. New investors included the corporate venture fund of WuXi AppTec Co. Ltd. (Shanghai:603259),...
11:01 , Jul 16, 2018 |  BC Extra  |  Financial News

DFJ leads Verge Genomics' $32M series A round

Neuroscience company Verge Genomics Inc. (San Francisco, Calif.) raised $32 million in a series A round led by DFJ. New investors included the corporate venture fund of WuXi AppTec Co. Ltd. (Shanghai:603259), ALS Investment Fund,...
11:00 , Jul 16, 2018 |  BioCentury  |  Finance

AI on the Verge

For its $32 million series A round, artificial intelligence-guided neurology company Verge Genomics Inc. sought an investor syndicate that reflected its multidisciplinary mind-set. DFJ led the round. New investors included the corporate venture fund of...
18:35 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Emulate raises $36M series C to improve Organ-Chips offering

Emulate Inc. (Boston, Mass.) raised on June 19 $36 million in a series C round led by Founders Fund. Fellow new investors ALS Investment Fund, SciFi VC and Glass Wall Syndicate also participated, as did...
11:00 , Jun 19, 2018 |  BC Extra  |  Financial News

Emulate raises $36M series C to improve Organ-Chips offering

Emulate Inc. (Boston, Mass.) raised $36 million in a series C round led by Founders Fund. Fellow new investors ALS Investment Fund, SciFi VC and Glass Wall Syndicate also participated, as did undisclosed existing investors....
22:01 , Nov 16, 2017 |  BC Extra  |  Financial News

Protein misfolding play Orphazyme prices IPO

Protein misfolding company Orphazyme A/S (CSE:ORPHA TEMP) was unchanged on Thursday after it debuted on NASDAQ Copenhagen, raising DKK 600 million ($94.1 million) in an IPO through the sale of 7.5 million shares at DKK...